ema retatrutide approval and the Grey Market: Buyer Beware – Sarah Hormachea October 27, 2025: U.K. regulators

Source: Jastreboff et al., NEJM 2023

Trying smaller, more frequent meals

weight loss (Phase 2/3 peak) | ~15% | ~22% | ~24% | | FDA Status | Approved (Wegovy, Ozempic) | Approved (Zepbound, Mounjaro) | Phase 3 (2026) | | Dosing frequency | Weekly | Weekly | Weekly | The additional glucagon receptor agonism is believed to be responsible for retatrutide's greater metabolic rate increase and enhanced fat oxidation compared to dual agonists

Ingredients like chicory inulin and clinically backed strains offer dual-action support for glucose concerns and appetite control

As your body adjusts to the medication, you may also experience improved blood sugar control, which can further enhance your weight loss results and overall health

GLP-1 analogues, such as semaglutide, alter appetite and glucose metabolism